News

January 10, 2018January 10, 2018

Breast Implants Associated with Small Increased Risk of Anaplastic Large-cell Lymphoma

News

A study found that one in 6,920 women with breast implants will develop anaplastic large-cell lymphoma (ALCL) in the breast before they reach the age of 75. Even though the ... Read more

January 9, 2018

FDA Cites Lack of Data About Blood Cancer Medications in Older People

News

Older patients are underrepresented in clinical trials of treatments for lymphoma and other blood cancers, despite being the largest patient group affected, researchers from the U.S. Food and Drug Administration ... Read more

January 8, 2018

Leukemia & Lymphoma Society Launches Navigating Cancer’s Network of Support

News

The Leukemia and Lymphoma Society (LLS) aims to leverage education about blood cancers, including leukemia, lymphoma and myeloma, through a new partnership with Navigating Cancer, a patient relationship management company. ... Read more

January 5, 2018

Cellectar Seeks FDA’s OK to Advance CLR 131 into Trials for Rare Pediatric Cancers

News

Cellectar Biosciences has filed an application with the U.S. Food and Drug Administration (FDA) to advance CLR 131 into a proposed Phase 1 clinical trial testing the investigational drug in children and teenagers with rare ... Read more

January 4, 2018

Atara Starts Two Phase 3 Trials of Treatment for Lymphoma That Arises from a Transplant

News

Atara Biotherapeutics is conducting two Phase 3 clinical trials of a treatment for a transplant-related disorder that can include lymphoma. The company developed tabelecleucel (ATA129) for people whose dormant Epstein-Barr virus can ... Read more

January 3, 2018

FDA to Review Adcetris, Chemo Combo as First-line Treatment for Advanced Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration (FDA) has agreed to review Adcetris (brentuximab vedotin) in combination with chemotherapy as a frontline treatment for patients with advanced Hodgkin’s lymphoma, according to Seattle Genetics. The supplemental Biologics License ... Read more

January 2, 2018

Verastem to Seek FDA Approval for Duvelisib to Treat SLL and CLL After Consistently Positive Trial Results

News

Verastem‘s duvelisib significantly delays disease progression or death in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to Phase 3 trial results. The trial, called ... Read more

December 22, 2017December 22, 2017

Benefits of 2 CAR T-cell Therapies May Justify Their High Price, ICER Report Argues

News

The clinical benefits of two recently approved CAR T-cell cancer therapies appear to justify their hefty price, a draft report by University of Colorado researchers suggests. The researchers — Melanie Whittington, ... Read more

December 21, 2017

Exercising Decreases Risk of Dying from Lymphoma, Mayo Clinic Study Shows

News

Exercising reduces the risk of dying from lymphoma, a Mayo Clinic study reports. Dr. Priyanka Pophali, a blood disease specialist at the Rochester, Minnesota-based healthcare organization, presented the findings at the 59th American ... Read more

December 20, 2017December 20, 2017

Key Genes in T-cell Lymphoma Patients Often Missing Agent That Blocks Cancer Signaling, Study Says

News

The tumor suppressor PD-1, which serves as shut-off switch to prevent damaged T-cells from continuing to develop and proliferate, is frequently missing in crucial genes of patients with T-cell lymphomas, a ... Read more